Crossmark

A novel combination of sitagliptin and melatonin ameliorates T2D manifestations: studies on experimental diabetic models

Published Online: 2023-01-24

Authors

Patel, R.

Parmar, N.

Palit, S. P.

Rathwa, N.

Begum, R. http://orcid.org/0000-0003-3446-0980
Funding

Funding for this research was provided by:

Department of Biotechnology, Ministry of Science and Technology, India (BT/PR12584/MED/31/289/2014)
License Information

Text and Data Mining valid from 2023-01-24

Version of Record valid from 2023-01-24
More Information

Article History

Received: 5 September 2022

Accepted: 16 January 2023

First Online: 24 January 2023

Declarations

:

: The authors declare that no competing interests exist.

: The animal study was approved by the Institutional Animal Ethical Committee (IAEC) (MSU/BC/13/2017) in accordance with the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines.

: For this type of study formal consent is not required.

Document is current